By Fineline Cube 
Germany-based Cyprumed GmbH has entered into a non-exclusive license and option agreement with Merck, Sharp & Dohme (MSD; NYSE: MRK). This strategic partnership grants MSD access to Cyprumed’s innovative drug delivery technology to develop oral formulations of its peptides, potentially transforming the delivery of peptide-based therapies.
Agreement Terms and Financials
Under the agreement, MSD secures non-exclusive global rights to utilize Cyprumed’s oral peptide delivery platform for an undisclosed number of targets. Additionally, MSD holds the option to exclusively license the technology for individual targets. Cyprumed stands to benefit from significant financial milestones, with potential payments totaling up to USD 493 million, including upfront, development, regulatory, and net sales milestones. Further payments may be triggered if MSD exercises its exclusive license option.
Technology and Market Potential
Cyprumed’s oral peptide delivery platform represents a breakthrough in drug delivery, addressing the challenges traditionally associated with oral administration of peptide-based drugs. This technology could significantly enhance patient compliance and convenience by offering a viable alternative to injectable formulations. MSD’s investment highlights the growing interest in oral peptide therapies and their potential to disrupt the market.
Development and Commercialization
MSD will be responsible for all aspects of research, development, manufacturing, and commercialization of products leveraging Cyprumed’s delivery technology. This comprehensive approach ensures that MSD can fully harness the potential of Cyprumed’s platform to bring novel oral peptide formulations to market.-Fineline Info & Tech